ImmunityBio receives Macau approval for Anktiva combo therapy
The regulatory milestone is ImmunityBio’s first authorisation for Anktiva in Asia.
Drug Development
BMS secures FDA and EC approvals for Opdivo in Hodgkin Lymphoma
Novartis to acquire SNV4818 from Synnovation
Congruence secures $39.5m to advance small molecule correctors pipeline
R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia
FDA issues CRL to Aldeyra’s reproxalap drug application
FDA accepts Sun Pharma’s Ilumya sBLA for psoriatic arthritis
Sentynl and PRG partner for Progerinin licence
